Finance

Lists
RLAY:NASDAQ
Relay Therapeutics Inc
$18.66
-2.35%
(-0.45) 1D
$19.25
+3.16% (+0.59)
After hours
Closed: Sep 9, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RLAY...
Open
$18.76
High
$19.18
Low
$18.54
Mkt. cap
4.09B
Avg. vol.
2.36M
Volume
0.00
52-wk high
$21.27
52-wk low
$3.86
EPS
-$1.57
Beta
1.69
Shares outstanding
219.14M
No. of employees
202
Open
$18.76
High
$19.18
Low
$18.54
Mkt. cap
4.09B
Avg. vol.
2.36M
Volume
0.00
52-wk high
$21.27
52-wk low
$3.86
EPS
-$1.57
Beta
1.69
Shares outstanding
219.14M
No. of employees
202
News stories
From web sources and news partners
About Relay Therapeutics Inc
CEO-
Employees202
Founded2015
Headquarters-
SectorBiotechnology
Websiterelaytx.com
Analyst ratings
Based on 9 analysts giving stock ratings to RLAY in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for RLAY in the last 3 months.
Highest
Current $18.66
$31.00 (+66.13%)
Average
$27.63 (+48.07%)
Lowest
$20.00 (+7.18%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
$29.00
+55.4%
08/21/2026
Priyanka Grover
J.P. Morgan
Buy
Maintained
$31.00
+66.1%
08/14/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
$26.00
+39.3%
08/10/2026
John Newman
Canaccord Genuity
Buy
Maintained
$29.00
+55.4%
08/06/2026
Boris Peaker
JonesTrading
Buy
Maintained
$20.00
+7.2%
08/07/2026
Etzer Darout
Barclays
Buy
Maintained
$30.00
+60.8%
08/07/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
08/06/2026
Chi Meng Fong
Bank of America Securities
Buy
Reiterated
$25.00
+34%
08/07/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$31.00
+66.1%
07/20/2026
Unknown Analyst
J.P. Morgan
Buy
Initiated
$28.00
+50.1%
07/08/2026
Bradley Canino
Guggenheim
Buy
Maintained
$26.00
+39.3%
05/25/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Maintained
$21.00
+12.5%
05/19/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$26.00
+39.3%
05/19/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$18.00
-3.5%
05/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$22.00
+17.9%
05/06/2026
Danya Ben-Hail
JonesTrading
Hold
Initiated
$18.00
-3.5%
04/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
7.00M
3.00M
350.00K
Cost of goods sold
67.89M
54.04M
70.56M
76.48M
Cost of revenue
67.89M
54.04M
70.56M
76.48M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.50M
13.59M
11.03M
14.69M
Operating expense
12.50M
13.59M
11.03M
14.69M
Total operating expenses
80.39M
67.63M
81.59M
91.17M
Operating income
-80.39M
-60.63M
-78.59M
-90.82M
Other non operating income
-165.00K
30.00K
-53.00K
2.00K
EBT including unusual items
-74.15M
-54.89M
-73.29M
-83.71M
EBT excluding unusual items
-74.15M
-54.89M
-73.29M
-83.71M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-74.15M
-54.89M
-73.29M
-83.71M
Net profit margin
-
-784.14%
-2,443.03%
-23,916.29%
Earnings per share
-0.43
-0.31
-0.41
-0.41
Interest and investment income
6.41M
5.71M
5.35M
7.12M
Interest expense
-
-
-
-
Net interest expenses
6.41M
5.71M
5.35M
7.12M
Depreciation and amortization charges
-
-
-
-
EBITDA
-79.64M
-60.03M
-78.09M
-90.46M
Gain or loss from assets sale
353.00K
35.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps